Osteoporosis is a common disease characterised by a systemic impairment of bone mass
and microarchitecture that results in fragility fractures. With an ageing population, the …

Osteoporosis is a common disease characterised by a systemic impairment of bone mass
and microarchitecture that results in fragility fractures. With an ageing population, the …

Since the identification of osteoporosis as a major health issue in aging populations and the
subsequent development of the first treatment modalities for its management, considerable …

Postmenopausal osteoporosis is a disease of high bone remodeling, with an imbalance of
bone resorption over bone formation, resulting in decreased bone mineral density and …

Osteoporosis is a worldwide health problem with a high prevalence. Agents for the treatment
of osteoporosis are classified as either antiresorptive or anabolic. Antiresorptive agents work …

Osteoporosis is characterised by a progressive loss of bone mass and microarchitecture
which leads to increased fracture risk. Some of the drugs available to date have shown …

Highlights•Selective cathepsin K inhibition inhibits bone resorption in clinical and preclinical
studies.•Wnt signaling promotes bone formation.•Blockade of Wnt inhibitors increases bone …

Introduction: The metabolic bone disease osteoporosis is a growing health and health-
economic problem worldwide. Bisphosphonates are the most widely used antiresorptive …

Osteoporosis is a skeletal disease associated with an imbalance between formation and
resorption, leading to net loss of bone mass, loss of bone microarchitecture, and …

Aims: To describe the mechanisms of action of denosumab, a novel antiresorptive agent,
contrasting it with other antiresorptive and anabolic osteoporosis treatments. Methods …